Predicting hospitalization among HIV-infected antiretroviral naïve patients starting HAART: Determining clinical markers and exploring social pathways

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 20, Issue 3, 2008, Pages 297-303

  Fielden, Sarah J ^a,b   Rusch, Melanie L A ^a,b,c   Levy, Adrian R ^a,b   Yip, Benita ^a   Wood, Evan ^a,b   Harrigan, Richard P ^a,b   Goldstone, Irene ^a,b   Guillemi, Silvia ^a   Montaner, Julio S ^a,b   Hogg, Robert S ^a,d  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD;

EID: 41349094378     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701561296     Document Type: Article

References (51)

1. Anis, A.H., Guh, D., Hogg, R.S., Wang, X.H., Yip, B., Craib, K.J.P., et al. (2000). The cost-effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics, 18, 393-404.
2. Anis, A.H., Hogg, R.S., Wang, X.H., Yip, B., Palepu, A., Montaner, J.S., et al. (1998). Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Pharmacoeconomics, 13, 697-705.
3. Bogart, L.M., Kelly, J.A., Catz, S.L., & Sosman, J.M. (2000). Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. Journal of AIDS, 23, 396-404.
4. Braitstein, P., Li, K., Tyndall, M., Spittal, P., O'Shaughnessy, M.V., Schilder, A., et al. (2003). Sexual violence among a cohort of injection drug users. Social Science and Medicine, 57, 561-569.
5. Chamberlayne, R., Green, B., Barer, M.L., Hertzman, C., Lawrence, W.J., & Sheps, S.B. (1998). Creating a population-based linked health database: A new resource for health services research. Canadian Journal of Public Health, 89, 270-273.
6. Chan, K.C., Yip, B., Hogg, R.S., Montaner, J.S., & O'Shaughnessy, M.V. (2002). Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS, 16, 1693-1695.
7. Detels, R., Tarwater, P., Phair, J.P., Margolick, J., Riddler, S.A., Munoz, A., et al. (2001). Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS, 15, 347-355.
8. Egger, M., May, M., Chene, G., Phillips, A.N., Ledergerber, B., Dabis, F., et al. (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet, 360, 119-129.
9. Floris-Moore, M., Lo, Y., Klein, R.S., Budner, N., Gourevitch, M.N., Moskaleva, G., et al. (2003). Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. Journal of AIDS, 34, 331-337.
10. Freedberg, K.A., Losina, E., Weinstein, M.C., Paltiel, A.D., Cohen, C.J., Seage, G.R., et al. (2001). The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medecine, 344, 824-831.
11. French, M.A., Price, P., & Stone, S.F. (2004). Immune restoration disease after antiretroviral therapy. AIDS, 18, 1615-1627.
12. Galai, N., Vlahov, D., Bareta, J.C., Wang, C., Cohn, S., & Sterling, T.R. (2005). Prognostic factors for survival differ according to CD4 cell count among HIV-infected injection drug users: Pre-HAART and HAART eras. Journal of AIDS, 38, 74-81.
13. Gardner, L.I., Klein, R.S., Szczech, L.A., Phelps, R.M., Tashima, K., Rompalo, A.M., et al. (2003). Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. Journal of AIDS, 34, 320-330.
14. Gebo, K.A., Diener-West, M., & Moore, R.D. (2001). Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. Journal of AIDS, 27, 143-152.
15. Gebo, K.A., Diener-West, M., & Moore, R.D. (2003). Hospitalization rates differ by hepatitis C status in an urban HIV cohort. Journal of AIDS, 34, 165-173.
16. Heath, K.V., Cornelisse, P.G., Strathdee, S.A., Palepu, A., Miller, M.L., Schechter, M.T., et al. (1999). HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men. International Journal of STD and AIDS, 10, 582-587.
17. Hogg, R.S., Craib, K.J., Willoughby, B., Sestak, P., Montaner, J.S., & Schechter, M.T. (1993). Sociodemographic correlates for risk-taking behaviour among HIV seronegative homosexual men. Canadian Journal of Public Health, 84, 423-426.
18. Hogg, R.S., Schechter, M.T., Schilder, A., Le, R., Strathdee, S.A., Goldstone, I.L., et al. (1995). Access to healthcare and geographic mobility of HIV/AIDS patients. AIDS Patient Care, 9, 297-302.
19. Hogg, R.S., Yip, B., Chan, K.J., Wood, E., Craib, K.J., O'Shaughnessy, M.V., et al. (2001). Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. Journal Of The American Medical Association, 286, 2568-2577.
20. Hogg, R.S., Yip, B., Kully, C., Craib, K.J., O'Shaughnessy, M.V., Schechter, M.T., et al. (1999). Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal, 160, 659-665.
21. Holmberg, S.D., Palella Jr, F.J., Lichtenstein, K.A., & Havlir, D.V. (2004). The case for earlier treatment of HIV infection. Clinical Infectious Diseases, 39, 1699-1704.
22. Kerr, T., Wood, E., Grafstein, E., Ishida, T., Shannon, K., Lai, C., et al. (2005). High rates of primary care and emergency department use among injection drug users in Vancouver. Journal of Public Health, 27, 62-66.
23. Krentz, H.B., Auld, M.C., & Gill, M.J. (2004). The high cost of medical care for patients who present late (CD4 <20 cells/mL) with HIV infection. HIV Medicine, 5, 93-98.
24. Kuyper, L.M., Hogg, R.S., Montaner, J.S., Schechter, M.T., & Wood, E. (2004). The cost of inaction on HIV transmission among injection drug users and the potential for effective interventions. Journal of Urban Health, 81, 655-660.
25. Manavi, K., McMillan, A., Ogilvie, M., & Scott, G. (2004). Heterosexual men and women with HIV test positive at a later stage of infection than homo or bisexual men. International Journal of STD and AIDS, 15, 811-814.
26. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., Monforte, A.D., et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet, 362, 22-29.
27. Mocroft, A., Monforte, A., Kirk, O., Johnson, M.A., Friis-Moller, N., Banhegyi, D., et al. (2004). Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Medicine, 5, 437-447.
28. Mocroft, A., Vella, S., Benfield, T.L., Chiesi, A., Miller, V., Gargalianos, P., et al. (1998). Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, 352, 1725-1730.
29. Mouton, Y., Alfandari, S., Valette, M., Cartier, F., Dellamonica, P., Humbert, G., et al. (1997). Impact of protease inhibitors on AIDS-defining events and hospitalizations in ten French AIDS reference centres. AIDS, 11, F101-F105.
30. Palella, F.J., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medecine, 338, 853-860.
31. Palepu, A., Strathdee, S.A., Hogg, R.S., Anis, A.H., Rae, S., Cornelisse, P.G., et al. (1999). The social determinants of emergency department and hospital use by injection drug users in Canada. Journal of Urban Health, 76, 409-418.
32. Palepu, A., Tyndall, M.W., Leon, H., Muller, J., O'Shaughnessy, M.V., Schechter, M.T., et al. (2001). Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal, 165, 415-420.
33. Paul, S., Gilbert, H.M., Ziecheck, W., Jacobs, O., & Sepkowitz, K.A. (1999). The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS, 13, 415-418.
34. Pulvirenti, J.J., Glowacki, R., Muppiddi, U., Surapaneni, N., Gail, C., Kohl, B., et al. (2003). Hospitalized HIV-infected patients in the HAART era: A view from the inner city. AIDS Patient Care STDs, 17, 565-573.
35. Rusch, M., Nixon, S., Schilder, A., Braitstein, P., Chan, K., & Hogg, R.S. (2004). Use of antiretroviral therapy among HIV-positive individuals living in British Columbia. AIDS Care, 16, 914-922.
36. Sabin, C.A., Smith, C.J., Gumley, H., Murphy, G., Lampe, F.C., Phillips, A.N., et al. (2004). Late presenters in the era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy. AIDS, 18, 2145-2151.
37. Shapiro, M.F., Morton, S.C., McCaffrey, D.F., Senterfitt, J.W., Fleishman, J.A., Perlman, J.F., et al. (1999). Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association, 281, 2305-2315.
38. Shelburne, S.A., Visnegarwala, F., Darcourt, J., Graviss, E.A., Giordano, T.P., White, A.C.J., et al. (2005). Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS, 19, 399-406.
39. Sterling, T.R., Chaisson, R.E., Keruly, J., & Moore, R.D. (2003). Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: Longer follow-up of an observational cohort study. Journal of Infectious Diseases, 188, 1659-1665.
40. Strathdee, S.A., Palepu, A., Cornelisse, P.G., Yip, B., O'Shaughnessy, M.V., Montaner, J.S., et al. (1998). Barriers to use of free antiretroviral therapy in injection drug users. Journal of the American Medical Association, 280, 547-549.
41. Tarwater, P.M., Gallant, J.E., Mellors, J.W., Gore, M.E., Phair, J.P., Detels, R., et al. (2004). Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS, 18, 2419-2423.
42. Tashima, K.T., Hogan, J.W., Gardner, L.I., Korkontzelou, C., Schoenbaum, E.E., Schuman, P., et al. (2001). A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clinical Infectious Diseases, 33, 2055-2060.
43. Weber, A.E., Chan, K., George, C., Hogg, R.S., Remis, R.S., Martindale, S., et al. (2001). Risk factors associated with HIV infection among young gay and bisexual men in Canada. Journal of AIDS, 28, 81-88.
44. Wohl, A.R., Lu, S., Odem, S., Sorvillo, F., Pegues, C.F., & Kerndt, P.R. (1998). Sociodemographic and behavioral characteristics of African-American women with HIV and AIDS in Los Angeles County, 1990-1997. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19, 413-420.
45. Wood, E., Hogg, R.S., Yip, B., Harrigan, P.R., & Montaner, J.S. (2004a). Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence. AIDS, 18, 2432-2434.
46. Wood, E., Hogg, R.S., Yip, B., Harrigan, P.R., O'Shaughnessy, M.V., & Montaner, J.S. (2003a). Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+cell count is 0.200 to 0.350 x 10(9) cells/L. Annals of Internal Medicine, 139, 810-816.
47. Wood, E., Hogg, R.S., Yip, B., Harrigan, P.R., O'Shaughnessy, M.V., & Montaner, J.S. (2004b). The impact of adherence on CD4 cell count responses among HIV-infected patients. Journal of AIDS, 35, 261-268.
48. Wood, E., Montaner, J.S., Chan, K., Tyndall, M.W., Schechter, M.T., Bangsberg, D., et al. (2002). Socioeconomic status, access to triple therapy and survival from HIV-disease since 1996. AIDS, 16, 2065-2072.
49. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., O'Shaughnessy, M.V., et al. (2003b). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal, 169, 656-661.
50. Wood, E., Yip, B., Hogg, R.S., Sherlock, C.H., Jahnke, N., Harrigan, R.P., et al. (2000). Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS, 14, 1955-1960.
51. Yeni, P.G., Hammer, S.M., Hirsch, M.S., Saag, M.S., Schechter, M., Carpenter, C.C.J., et al. (2004). Treatment for adult HIV infection: 2004 recommendations of the international AIDS society-USA panel. Journal of the American Medical Association, 292, 251-265.